New hope for colorectal cancer: immune booster plus chemotherapy tested
NCT ID NCT07359456
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding the immune-boosting drug ivonescimab to standard chemotherapy (FOLFIRI) helps people with advanced colorectal cancer live longer without their cancer growing. It compares this new combination to the current standard of FOLFIRI plus bevacizumab. The study includes 130 adults whose cancer has not spread to the liver and who have already tried one prior treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ivonescimab (a drug that helps the immune system fight cancer) combined with FOLFIRI chemotherapy
What this could lead to
If it works, this could offer a more effective second-line treatment option for people with a common type of advanced colorectal cancer that hasn't spread to the liver.
What could go wrong
This is an early phase 2 trial with only 130 participants, so results may not apply to everyone. The new combination may not work better than the current standard and could have side effects like immune-related reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CH d'Auxerre
Auxerre, France
Contact
-
CH de Calais
Calais, France
Contact
-
CHRU de Nancy
Nancy, France
Contact Email: •••••@•••••
-
CHU de Poitiers
Poitiers, France
Contact Email: •••••@•••••
-
CHU de Reims
Reims, France
Contact Email: •••••@•••••
-
CHU de Rouen
Rouen, France
Contact Email: •••••@•••••
-
Centre François Baclesse
Caen, France
Contact Email: •••••@•••••
-
Centre Hospitalier de Beuvry
Beuvry, France
Contact
-
Centre Hospitalier de Valenciennes
Valenciennes, France
Contact
-
Centre Léon Bérard
Lyon, France
Contact
-
Centre Oscar Lambret
Lille, France
Contact Email: •••••@•••••
-
Gustave Roussy
Villejuif, France
Contact Email: •••••@•••••
-
Hôpital Européen de Marseille
Marseille, France
Contact
-
Hôpital Privé des côtes d'Armor
Plérin, France
Contact
-
Hôpital Saint Antoine - APHP
Paris, France
Contact Email: •••••@•••••
-
Hôpital Saint Louis - APHP
Paris, France
Contact Email: •••••@•••••
-
Hôpital la Timone
Marseille, France
Contact Email: •••••@•••••
-
Institut Andrée Dutreix
Coudekerque-Branche, France
Contact
-
Institut Jean Godinot
Reims, France
Contact Email: •••••@•••••
-
Institut Paoli Calmettes
Marseille, France
Contact Email: •••••@•••••
-
Institut de Cancérologie de l'Ouest - Site René Gauducheau
Saint-Herblain, France
Contact
-
Polyclinique Saint Côme
Compiègne, France
Contact